Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320411 | 1.00 | MAPT (0.50) | MAPTALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL3320351 | 0.86 | CNR1 (0.50) | MAPTALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL3320090 | 0.86 | CNR1 (0.51) | MAPTALDH1A1LMNAHTTPOLB | |
| SCHEMBL3320349 | 0.86 | CNR1 (0.50) | MAPTALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL3320089 | 0.86 | CNR1 (0.51) | MAPTALDH1A1LMNAHTTPOLB | |
| SCHEMBL3320490 | 0.86 | LMNA (0.48) | MAPTALDH1A1LMNANPSR1KMT2A | |
| SCHEMBL3320488 | 0.86 | LMNA (0.48) | MAPTALDH1A1LMNANPSR1KMT2A | |
| SCHEMBL3320188 | 0.85 | MAPT (0.49) | MAPTALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL3320190 | 0.85 | MAPT (0.49) | MAPTALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL3321294 | 0.84 | L3MBTL1 (0.46) | MAPTALDH1A1SMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-7186719-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2007-03-06 | — | — | US | disclosed |
| US-20050065095-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2005-03-24 | — | — | US | disclosed |
| US-6846825-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2005-01-25 | — | — | US | disclosed |
| EP-1202968-A2 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010834-A9 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARM (GB) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001010834-A2 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065095-A1 | Antibacterial agents | NQO2, DAO, Q6ZSR9 | MAPT 4845/4885ALDH1A1 2137/4885SMN1; SMN2 4495/4885 |
| US-20100125075-A1 | Antibacterial Agents | NQO2, DAO, Q6ZSR9 | MAPT 4855/4885ALDH1A1 2288/4885SMN1; SMN2 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.